Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review

Introduction Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in therapy 2023-01, Vol.40 (1), p.117-132
Hauptverfasser: Lohsiriwat, Varut, Sheikh, Parvez, Bandolon, Robert, Ren, Dong-Lin, Roslani, April Camilla, Schaible, Kassandra, Freitag, Andreas, Martin, Monique, Yaltirik, Pelin, Godeberge, Philippe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 132
container_issue 1
container_start_page 117
container_title Advances in therapy
container_volume 40
creator Lohsiriwat, Varut
Sheikh, Parvez
Bandolon, Robert
Ren, Dong-Lin
Roslani, April Camilla
Schaible, Kassandra
Freitag, Andreas
Martin, Monique
Yaltirik, Pelin
Godeberge, Philippe
description Introduction Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD. Methods Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews. Results The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most ( n  = 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments. Conclusion The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence. Graphical abstract Plain Language Summary Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world e
doi_str_mv 10.1007/s12325-022-02351-7
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9859842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2732540359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-5da4adc4c656871b86da2dad9a7900a59f9d017b853086e804038e454cbe27b3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhC3BAPnIJ-G_scECqWmiRKoGWPXBAsib27K6rJC52UtRvj-mWCi4cRnN4b96M5kfIS87ecMbM28KFFLphQtSSmjfmEVlx2-qmlnhMVswo3ghpvx2RZ6VcMSaY0fYpOZKtlNxotSLf1-iXnHHySNcwY6EwBfplD3kEn4a0ix4GuskI84jTTLcp0wscU877FEOVzmJBKPiOntCvt2XGEebo6RpvIv58Tp5sYSj44r4fk83HD5vTi-by8_mn05PLxivVzo0OoCB45VvdWsN72wYQAUIHpmMMdLftAuOmt1oy26JlikmLSivfozC9PCbvD7HXSz9i8PXODIO7znGEfOsSRPevMsW926Ub11ndWSVqwOv7gJx-LFhmN8bicRhgwrQUJ0z9c12qu2oVB6vPqZSM24c1nLnfVNyBiqtU3B0VZ-rQq78PfBj5g6Ea5MFQqjTtMLurtOSp_ux_sb8AioOZww</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2732540359</pqid></control><display><type>article</type><title>Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Lohsiriwat, Varut ; Sheikh, Parvez ; Bandolon, Robert ; Ren, Dong-Lin ; Roslani, April Camilla ; Schaible, Kassandra ; Freitag, Andreas ; Martin, Monique ; Yaltirik, Pelin ; Godeberge, Philippe</creator><creatorcontrib>Lohsiriwat, Varut ; Sheikh, Parvez ; Bandolon, Robert ; Ren, Dong-Lin ; Roslani, April Camilla ; Schaible, Kassandra ; Freitag, Andreas ; Martin, Monique ; Yaltirik, Pelin ; Godeberge, Philippe</creatorcontrib><description>Introduction Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD. Methods Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews. Results The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most ( n  = 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments. Conclusion The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence. Graphical abstract Plain Language Summary Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world evidence (RWE) studies reporting the epidemiology or recurrence of HD as well as published SLRs that combined the results of multiple studies (meta-analyses) on treatment for adults with HD. Forty of 2037 articles identified by the search were considered relevant, and four others identified by clinicians were also included (total = 44; 39 RWE, 5 meta-analyses). Review of the RWE articles revealed that HD epidemiology was determined differently between studies. Only 23 reported recurrence rates (up to 56.5%) after surgery or treatment with phlebotonic drugs (drugs that improve blood flow in veins). Most (19/23) reported recurrence rates of 20% or less. Risk factors for recurrence were similar to usual HD risk factors (e.g., constipation, male gender, age) in addition to time since treatment. Phlebotonic agents, including those made from plant extracts (micronized purified flavonoid fractions, MPFFs) improved hemorrhoidal symptoms compared with placebo or no treatment. In one meta-analysis, MPFF was the only phlebotonic to significantly reduce recurrence risk versus no treatment or placebo. Overall, more research is needed to compare treatments and determine optimal treatment duration to prevent recurrence. BeGGY4JXaFY15gccdi8jpH Author-narrated video abstract</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-022-02351-7</identifier><identifier>PMID: 36331754</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Adult ; Cardiology ; Endocrinology ; Flavonoids ; Hemorrhage ; Hemorrhoids - drug therapy ; Hemorrhoids - epidemiology ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine &amp; Public Health ; Meta-Analysis as Topic ; Oncology ; Pharmacology/Toxicology ; Review ; Rheumatology ; Risk Factors</subject><ispartof>Advances in therapy, 2023-01, Vol.40 (1), p.117-132</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-5da4adc4c656871b86da2dad9a7900a59f9d017b853086e804038e454cbe27b3</citedby><cites>FETCH-LOGICAL-c446t-5da4adc4c656871b86da2dad9a7900a59f9d017b853086e804038e454cbe27b3</cites><orcidid>0000-0001-5599-8654 ; 0000-0002-2252-9509 ; 0000-0003-2153-2930 ; 0000-0003-2458-965X ; 0000-0003-4645-9864</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-022-02351-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-022-02351-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36331754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lohsiriwat, Varut</creatorcontrib><creatorcontrib>Sheikh, Parvez</creatorcontrib><creatorcontrib>Bandolon, Robert</creatorcontrib><creatorcontrib>Ren, Dong-Lin</creatorcontrib><creatorcontrib>Roslani, April Camilla</creatorcontrib><creatorcontrib>Schaible, Kassandra</creatorcontrib><creatorcontrib>Freitag, Andreas</creatorcontrib><creatorcontrib>Martin, Monique</creatorcontrib><creatorcontrib>Yaltirik, Pelin</creatorcontrib><creatorcontrib>Godeberge, Philippe</creatorcontrib><title>Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><addtitle>Adv Ther</addtitle><description>Introduction Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD. Methods Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews. Results The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most ( n  = 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments. Conclusion The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence. Graphical abstract Plain Language Summary Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world evidence (RWE) studies reporting the epidemiology or recurrence of HD as well as published SLRs that combined the results of multiple studies (meta-analyses) on treatment for adults with HD. Forty of 2037 articles identified by the search were considered relevant, and four others identified by clinicians were also included (total = 44; 39 RWE, 5 meta-analyses). Review of the RWE articles revealed that HD epidemiology was determined differently between studies. Only 23 reported recurrence rates (up to 56.5%) after surgery or treatment with phlebotonic drugs (drugs that improve blood flow in veins). Most (19/23) reported recurrence rates of 20% or less. Risk factors for recurrence were similar to usual HD risk factors (e.g., constipation, male gender, age) in addition to time since treatment. Phlebotonic agents, including those made from plant extracts (micronized purified flavonoid fractions, MPFFs) improved hemorrhoidal symptoms compared with placebo or no treatment. In one meta-analysis, MPFF was the only phlebotonic to significantly reduce recurrence risk versus no treatment or placebo. Overall, more research is needed to compare treatments and determine optimal treatment duration to prevent recurrence. BeGGY4JXaFY15gccdi8jpH Author-narrated video abstract</description><subject>Adult</subject><subject>Cardiology</subject><subject>Endocrinology</subject><subject>Flavonoids</subject><subject>Hemorrhage</subject><subject>Hemorrhoids - drug therapy</subject><subject>Hemorrhoids - epidemiology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Meta-Analysis as Topic</subject><subject>Oncology</subject><subject>Pharmacology/Toxicology</subject><subject>Review</subject><subject>Rheumatology</subject><subject>Risk Factors</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EokvhC3BAPnIJ-G_scECqWmiRKoGWPXBAsib27K6rJC52UtRvj-mWCi4cRnN4b96M5kfIS87ecMbM28KFFLphQtSSmjfmEVlx2-qmlnhMVswo3ghpvx2RZ6VcMSaY0fYpOZKtlNxotSLf1-iXnHHySNcwY6EwBfplD3kEn4a0ix4GuskI84jTTLcp0wscU877FEOVzmJBKPiOntCvt2XGEebo6RpvIv58Tp5sYSj44r4fk83HD5vTi-by8_mn05PLxivVzo0OoCB45VvdWsN72wYQAUIHpmMMdLftAuOmt1oy26JlikmLSivfozC9PCbvD7HXSz9i8PXODIO7znGEfOsSRPevMsW926Ub11ndWSVqwOv7gJx-LFhmN8bicRhgwrQUJ0z9c12qu2oVB6vPqZSM24c1nLnfVNyBiqtU3B0VZ-rQq78PfBj5g6Ea5MFQqjTtMLurtOSp_ux_sb8AioOZww</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Lohsiriwat, Varut</creator><creator>Sheikh, Parvez</creator><creator>Bandolon, Robert</creator><creator>Ren, Dong-Lin</creator><creator>Roslani, April Camilla</creator><creator>Schaible, Kassandra</creator><creator>Freitag, Andreas</creator><creator>Martin, Monique</creator><creator>Yaltirik, Pelin</creator><creator>Godeberge, Philippe</creator><general>Springer Healthcare</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5599-8654</orcidid><orcidid>https://orcid.org/0000-0002-2252-9509</orcidid><orcidid>https://orcid.org/0000-0003-2153-2930</orcidid><orcidid>https://orcid.org/0000-0003-2458-965X</orcidid><orcidid>https://orcid.org/0000-0003-4645-9864</orcidid></search><sort><creationdate>20230101</creationdate><title>Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review</title><author>Lohsiriwat, Varut ; Sheikh, Parvez ; Bandolon, Robert ; Ren, Dong-Lin ; Roslani, April Camilla ; Schaible, Kassandra ; Freitag, Andreas ; Martin, Monique ; Yaltirik, Pelin ; Godeberge, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-5da4adc4c656871b86da2dad9a7900a59f9d017b853086e804038e454cbe27b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Cardiology</topic><topic>Endocrinology</topic><topic>Flavonoids</topic><topic>Hemorrhage</topic><topic>Hemorrhoids - drug therapy</topic><topic>Hemorrhoids - epidemiology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Meta-Analysis as Topic</topic><topic>Oncology</topic><topic>Pharmacology/Toxicology</topic><topic>Review</topic><topic>Rheumatology</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lohsiriwat, Varut</creatorcontrib><creatorcontrib>Sheikh, Parvez</creatorcontrib><creatorcontrib>Bandolon, Robert</creatorcontrib><creatorcontrib>Ren, Dong-Lin</creatorcontrib><creatorcontrib>Roslani, April Camilla</creatorcontrib><creatorcontrib>Schaible, Kassandra</creatorcontrib><creatorcontrib>Freitag, Andreas</creatorcontrib><creatorcontrib>Martin, Monique</creatorcontrib><creatorcontrib>Yaltirik, Pelin</creatorcontrib><creatorcontrib>Godeberge, Philippe</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lohsiriwat, Varut</au><au>Sheikh, Parvez</au><au>Bandolon, Robert</au><au>Ren, Dong-Lin</au><au>Roslani, April Camilla</au><au>Schaible, Kassandra</au><au>Freitag, Andreas</au><au>Martin, Monique</au><au>Yaltirik, Pelin</au><au>Godeberge, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Ther</stitle><addtitle>Adv Ther</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>40</volume><issue>1</issue><spage>117</spage><epage>132</epage><pages>117-132</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Introduction Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD. Methods Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews. Results The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most ( n  = 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments. Conclusion The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence. Graphical abstract Plain Language Summary Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world evidence (RWE) studies reporting the epidemiology or recurrence of HD as well as published SLRs that combined the results of multiple studies (meta-analyses) on treatment for adults with HD. Forty of 2037 articles identified by the search were considered relevant, and four others identified by clinicians were also included (total = 44; 39 RWE, 5 meta-analyses). Review of the RWE articles revealed that HD epidemiology was determined differently between studies. Only 23 reported recurrence rates (up to 56.5%) after surgery or treatment with phlebotonic drugs (drugs that improve blood flow in veins). Most (19/23) reported recurrence rates of 20% or less. Risk factors for recurrence were similar to usual HD risk factors (e.g., constipation, male gender, age) in addition to time since treatment. Phlebotonic agents, including those made from plant extracts (micronized purified flavonoid fractions, MPFFs) improved hemorrhoidal symptoms compared with placebo or no treatment. In one meta-analysis, MPFF was the only phlebotonic to significantly reduce recurrence risk versus no treatment or placebo. Overall, more research is needed to compare treatments and determine optimal treatment duration to prevent recurrence. BeGGY4JXaFY15gccdi8jpH Author-narrated video abstract</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>36331754</pmid><doi>10.1007/s12325-022-02351-7</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0001-5599-8654</orcidid><orcidid>https://orcid.org/0000-0002-2252-9509</orcidid><orcidid>https://orcid.org/0000-0003-2153-2930</orcidid><orcidid>https://orcid.org/0000-0003-2458-965X</orcidid><orcidid>https://orcid.org/0000-0003-4645-9864</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0741-238X
ispartof Advances in therapy, 2023-01, Vol.40 (1), p.117-132
issn 0741-238X
1865-8652
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9859842
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adult
Cardiology
Endocrinology
Flavonoids
Hemorrhage
Hemorrhoids - drug therapy
Hemorrhoids - epidemiology
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Meta-Analysis as Topic
Oncology
Pharmacology/Toxicology
Review
Rheumatology
Risk Factors
title Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A18%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recurrence%20Rates%20and%20Pharmacological%20Treatment%20for%20Hemorrhoidal%20Disease:%20A%20Systematic%20Review&rft.jtitle=Advances%20in%20therapy&rft.au=Lohsiriwat,%20Varut&rft.date=2023-01-01&rft.volume=40&rft.issue=1&rft.spage=117&rft.epage=132&rft.pages=117-132&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-022-02351-7&rft_dat=%3Cproquest_pubme%3E2732540359%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2732540359&rft_id=info:pmid/36331754&rfr_iscdi=true